P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY

• Thierry Facon,
• Philippe Moreau,
• Ivan Špicka,
• Kenshi Suzuki,
• Kwee Yong,
• Joseph Mikhael,
• Taro Fukao,
• Kamlesh Bisht,
• Nicole Armstrong,
• Sandrine Macé,
• Marie-Laure Risse,
• Thomas Martin

Affiliations

Thierry Facon

1 Department of Hematology, Lille University Hospital

Philippe Moreau

2 Department of Hematology, University Hospital Hôtel-Dieu

Ivan Špicka

3 Department of Hematology, 1st Faculty of Medicine, Charles University and General Hospital

Kenshi Suzuki

4 Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center

Kwee Yong

5 Department of Haematology, University College Hospital

Joseph Mikhael

6 Translational Genomics Research Institute, City of Hope Cancer Center

Taro Fukao

7 Sanofi, Global Oncology

Kamlesh Bisht

7 Sanofi, Global Oncology

Nicole Armstrong

8 Sanofi, Global Medical Affairs

Sandrine Macé

9 Sanofi, Research and Development

Marie-Laure Risse

9 Sanofi, Research and Development

Thomas Martin

10 University of California San Francisco Medical Center